- Research article
- Open Access
Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways
Arthritis Research & Therapy volume 13, Article number: R184 (2011)
Adiponectin is an adipokine that regulates energy metabolism and insulin sensitivity, but recent studies have pointed also to a role in inflammation and arthritis. The purpose of the present study was to investigate the association and effects of adiponectin on inflammation and cartilage destruction in osteoarthritis (OA).
Cartilage and blood samples were collected from 35 male OA patients undergoing total knee replacement surgery. Preoperative radiographs were evaluated using Ahlbäck classification criteria for knee OA. Circulating concentrations of adiponectin and biomarkers of OA, that is, cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase 3 (MMP-3), were measured. Cartilage samples obtained at the time of surgery were cultured ex vivo, and the levels of adiponectin, nitric oxide (NO), IL-6, MMP-1 and MMP-3 were determined in the culture media. In addition, the effects of adiponectin on the production of NO, IL-6, MMP-1 and MMP-3 were studied in cartilage and in primary chondrocyte cultures.
Plasma adiponectin levels and adiponectin released from OA cartilage were higher in patients with the radiologically most severe OA (Ahlbäck grades 4 and 5) than in patients with less severe disease (Ahlbäck grades 1 to 3). Plasma adiponectin concentrations correlated positively with biomarkers of OA, that is, COMP (r = 0.55, P = 0.001) and MMP-3 (r = 0.34, P = 0.046). Adiponectin was released by OA cartilage ex vivo, and it correlated positively with production of NO (r = 0.43, P = 0.012), IL-6 (r = 0.42, P = 0.018) and MMP-3 (r = 0.34, P = 0.051). Furthermore, adiponectin enhanced production of NO, IL-6, MMP-1 and MMP-3 in OA cartilage and in primary chondrocytes in vitro in a mitogen-activated protein kinase (MAPK)-dependent manner.
The findings of this study show that adiponectin is associated with, and possibly mediates, cartilage destruction in OA.
Adiponectin belongs to the adipokine hormones, which were initially found to be synthesized by white adipose tissue and to control appetite and metabolism. Adiponectin was discovered in 1995 by Scherer et al. , and it was first named Acrp30 (adipocyte complement-related protein of 30 kDa). Adiponectin has been found to improve insulin sensitivity [2, 3] and to have antiarthrogenic properties . Interestingly, adiponectin has also been identified as a regulatory factor in inflammation and arthritis [5–8].
Adiponectin can be found in synovial fluid from osteoarthritis (OA) patients [9, 10]. Tissues in the joint, including synovium, meniscus, osteophytes, cartilage, bone and fat, have been reported to produce adiponectin [10–12]. The biological effects of adiponectin are mediated through two adiponectin receptor subtypes, adiponectin receptor type 1 (AdipoR1) and adiponectin receptor type 2 (AdipoR2), which have been shown to be expressed in articular cartilage, bone and synovial tissue [13, 14].
In arthritis models and in joint tissues, adiponectin has been postulated to have both pro- and anti-inflammatory effects. Adiponectin has been reported to increase the production of cartilage-degrading matrix metalloproteinase (MMP) enzymes, cytokines and prostaglandin E2 in chondrocytes and in synovial fibroblasts [11, 14–19]. By contrast, intraarticularly injected adiponectin has been reported to mitigate the severity of collagen-induced arthritis in the mouse and to decrease immunohistochemically detected expression of TNF, IL-1 and MMP-3 . Recently, high circulating adiponectin was found to correlate with cartilage degradation in patients with rheumatoid arthritis (RA) [21–23], although partly contradictory results have also been published [24, 25].
Adiponectin has emerged as a regulator of immune responses and inflammatory arthritis [5–7], but its role in OA and cartilage degradation is controversial and, in many aspects, poorly known. The purpose of the present study was to investigate whether adiponectin is associated with radiographic severity or biomarkers of OA or with inflammatory and/or destructive factors released by cartilage samples obtained from OA patients. Since mitogen-activated protein kinase (MAPK) pathways have been proposed as therapeutic targets in OA [26, 27], we decided also to study the possible involvement of these pathways in adiponectin-induced responses in OA cartilage.
Materials and methods
Patients and clinical studies
The patients in this study fulfilled the American College of Rheumatology classification criteria for OA . Preoperative radiographs, blood samples and cartilage tissue were collected from 35 male patients with OA (means ± SEM: age = 69.5 ± 1.6 years, body mass index (BMI) = 29.3 ± 0.8 kg/m2) undergoing total knee replacement surgery at Coxa Hospital for Joint Replacement, Tampere, Finland. Radiographs were evaluated according to the Ahlbäck criteria, grades I to V, with grade V representing the most severe findings . Plasma and serum samples were stored at -80°C until analyzed for cartilage oligomeric matrix protein (COMP), MMP-3 and adiponectin. Cartilage samples were processed as described below, and the amounts of adiponectin, NO, IL-6, MMP-1 and MMP-3 released by the cartilage ex vivo during a 42-hour incubation were measured as described below. The study was approved by the Ethics Committee of Tampere University Hospital and carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patients.
Leftover pieces of OA cartilage from knee joint replacement surgery were used. Full-thickness pieces of articular cartilage from femoral condyles, tibial plateaus and patellar surfaces showing macroscopic features of early OA were removed aseptically from subchondral bone with a scalpel, cut into small pieces and cultured in DMEM with GIBCO GlutaMAX-I supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml) and amphotericin B (250 ng/ml) (all from Invitrogen/Life Technologies, Carlsbad, CA, USA) at 37°C in a humidified 5% carbon dioxide atmosphere.
Cartilage samples were incubated for 42 hours with or without adiponectin (recombinant human adiponectin produced in HEK cells; BioVendor Research and Diagnostic Products, Modřice, Czech Republic) and the MAPK inhibitors PD98059 (Erk1/2 inhibitor, 10 μM; Promega, Madison, WI, USA), SB220025 (p38 inhibitor, 0.5 μM; Calbiochem/Merck KGaA, Darmstadt, Germany) and SP600125 (JNK inhibitor, 10 μM; Calbiochem/Merck KGaA). The concentrations of adiponectin and MAPK inhibitors used in the experiments were based on preliminary experiments and studies previously carried out in our laboratory [30–32]. After the experiments, the cartilage explants were weighed and the results were expressed per milligram of cartilage. The culture media were kept at -20°C until analyzed.
Primary chondrocyte experiments
The leftover pieces of OA cartilage were processed the same way as cartilage for cartilage cultures (see above). Cartilage pieces were washed with PBS, and chondrocytes were isolated by enzymatic digestion for 16 hours at 37°C in a shaker by using a collagenase enzyme blend (1 mg/ml Liberase TM Research Grade medium; Roche, Mannheim, Germany). Isolated chondrocytes were washed and plated on 24-well plates (1.5 × 105 cells/ml) in culture medium (DMEM with supplements; see above) containing 10% fetal bovine serum. Cells were treated with increasing concentrations of adiponectin (0.1 to 3 μg/ml) for 24 hours. The culture media were kept at -20°C until analyzed. Concentrations of NO, IL-6, MMP-1 and MMP-3 were determined in culture media as described below. To investigate MAPK activation (phosphorylation), cells were treated with adiponectin for 30 or 60 minutes and processed for Western blot analysis.
Concentrations of nitrite, a stable metabolite of NO in aqueous solutions, were measured by Griess reaction .
Measurement of adiponectin, COMP, MMP-1, MMP-3 and IL-6
Concentrations of adiponectin, COMP, MMP-1, MMP-3 and IL-6 in plasma, serum and/or medium samples were determined by performing ELISA with commercial reagents (adiponectin, MMP-1 and MMP-3: R&D Systems Europe Ltd, Abindgon, UK; COMP: BioVendor; IL-6: Sanquin, Amsterdam, The Netherlands).
Western blot analysis
Western blot analysis was performed as previously described  using the following antibodies: rabbit anti-human pAb inducible nitric oxide synthase (iNOS), actin and c-Jun N-terminal kinase (JNK) antibodies, and horseradish-conjugated goat anti-rabbit immunoglobulin G antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and rabbit anti-human pAb p38, phospho-p38, phospho-JNK, extracellular signal-regulated kinase 1/2 (Erk1/2) and phospho-Erk1/2 antibodies from Cell Signaling Technology, Inc (Beverly, MA, USA).
Data were analyzed using SPSS version 17.0 for Windows software (SPSS Inc, Chicago, IL, USA) and GraphPad InStat version 3.00 software (GraphPad Software, San Diego, CA, USA). The results are presented as means ± SEM unless otherwise indicated. Pearson's correlation analysis was carried out, and r values over +0.3 and under -0.3 were considered to indicate a correlation. Differences between groups were tested by one-way analysis of variance (ANOVA) or repeated-measures ANOVA, followed by Fisher's least significant difference test or the Bonferroni correction for multiple comparisons when appropriate. P-values less than 0.05 were considered significant. Standard multiple regression analysis was used to predict circulating biomarker levels (COMP and MMP-3) when adiponectin, age and BMI were set as independent variables. Nonstandardized regression coefficients (β) and coefficients of determination squared (R2) with the related P-values were calculated. Binary logistic regression was used to compute (BMI or age-adjusted) ORs for plasma adiponectin and adiponectin released by cartilage to predict the most severe radiographic findings (Ahlbäck grade 4 or 5 vs grades 1 to 3). A statistician was consulted regarding the statistical analysis.
Correlation between plasma adiponectin and biomarkers of osteoarthritis
Thirty-five male OA patients were included in the study. Mean adiponectin concentration in plasma was 2.5 ± 0.2 μg/ml, and no correlation between plasma adiponectin and BMI was found (r = -0.15, P = 0.379). Interestingly, adiponectin correlated positively with the biomarkers of OA, that is, COMP (r = 0.55, P = 0.001) (Figure 1A) and MMP-3 (r = 0.34, P = 0.046) (Figure 1B), pointing to a possible connection between adiponectin and cartilage matrix degradation.
In multiple regression analysis, where serum COMP was set as a dependent variable and plasma adiponectin, age and BMI were set as predictive variables, adiponectin (β (that is, expected change in COMP with 1-U change in adiponectin) = 1.7; P = 0.010), but not BMI (β = -0.10, P = 0.566) or age (β = 0.14, P = 0.160), was a significant determinant of COMP (R2 = 0.39 and P = 0.001 for model). Also, adiponectin was a significant determinant of MMP-3 when it was set alone as an independent variable (β = 0.85, P = 0.046; R2 = 0.12 and P = 0.046 for model). Addition of BMI or age as independent variables did not improve the model (R2 = 0.15, P = 0.070 or R2 = 0.14, P = 0.089, respectively).
Plasma adiponectin levels and radiographic severity of osteoarthritis
Preoperative radiographs of the knees were evaluated by Ahlbäck classification from grades 1 to 5, with grade 5 representing the most severe findings . Grades 1 and 2, and 4 and 5 were combined to create more equally distributed subgroups. Mean plasma adiponectin concentrations were higher in the grades 4 and 5 group than in the grade 3 and grades 1 and 2 groups (Figure 2A), but there was no difference between the grades 1 and 2 group and the grade 3 group. There were no significant differences in age or BMI between the radiographic subgroups, but serum COMP was higher in the grades 4 and 5 group than in the grade 3 group and the grades 1 and 2 group (P = 0.012 and P = 0.006, respectively) (Table 1). Binary logistic regression analysis was used to further evaluate whether adiponectin is associated with the radiographic severity of OA (Ahlbäck grades 4 and 5 group vs Ahlbäck grades 1 to 3 group). When set alone in the model, plasma adiponectin and cartilage culture medium adiponectin, but not BMI or age, were significant explanatory factors of radiographic severity (Table 2). After adjusting for BMI, plasma adiponectin was a significant predictor of disease severity and almost statistically significant after adjusting for age (Table 2). Adiponectin measured in the cartilage culture media was a significant predictor of OA severity after controlling for age and BMI (Table 2).
Production of adiponectin and inflammatory and/or degrading factors by osteoarthritis cartilage ex vivo
Cartilage samples were obtained during joint replacement surgery from the same patients from whom the preoperative radiographs and the blood samples had been collected (see above), and tissue culture experiments were carried out. The amounts of adiponectin, NO, IL-6, MMP-1 and MMP-3 released from the cartilage into the culture medium during 42-hour incubation were measured. Adiponectin release was increased in patients with the radiographically most severe OA (Ahlbäck grades 4 and 5) as compared to patients in grades 1 and 2 and those in grade 3 (P = 0.004 and P < 0.001, respectively) (Figure 2B). Interestingly, adiponectin levels in the cartilage culture media correlated positively with those of NO (r = 0.43, P = 0.012) (Figure 3A), IL-6 (r = 0.42, P = 0.018) (Figure 3B) and MMP-3 (r = 0.34, P = 0.051) (Figure 3C), whereas no correlation between adiponectin and MMP-1 production was found (r = 0.17, P = 0.31).
Effect of adiponectin on osteoarthritis cartilage and primary chondrocytes in vitro
To further evaluate the role of adiponectin in OA, we studied the effect of this adipokine on MAPK phosphorylation (that is, activation) and on NO, IL-6, MMP-1 and MMP-3 production in primary chondrocytes from OA patients. Adiponectin treatment resulted in time-dependent phosphorylation of p38, Erk1/2 and JNK in primary OA chondrocytes that was obvious within 30 minutes and decreased toward baseline by 60 minutes (Figure 4). Adiponectin also enhanced NO, IL-6, MMP-1 and MMP-3 production in primary OA chondrocytes in a dose-dependent manner (Figure 5). Because cartilage matrix is an important regulator of chondrocyte metabolism, we wanted to investigate the effects of adiponectin on OA cartilage in tissue culture. Owing to the limited amount of tissue available for the experiments, one concentration of adiponectin (1 μg/ml) was selected based on the cell culture studies (Figure 5) and previously published data on adiponectin levels in OA synovial fluid [9, 10, 12, 35]. Adiponectin enhanced NO, IL-6, MMP-1 and MMP-3 production and iNOS expression in OA cartilage culture, and their production was suppressed by the p38 MAPK inhibitor SB220025 (0.5 μM) (Figure 6). In addition, the Erk1/2 inhibitor PD98059 (10 μM) and the JNK inhibitor SP600125 (10 μM) inhibited adiponectin-induced production of IL-6 and NO, as well as expression of iNOS, in a statistically significant manner, whereas their effect on MMP-1 and MMP-3 was smaller and did not reach statistical significance (Figure 6).
Adiponectin is found in OA joints, and proinflammatory and catabolic effects have been reported [9, 10, 13–19]. On the basis of our findings of the present study, we show for the first time that the circulating adiponectin concentrations correlate positively with the levels of the widely used biomarkers of OA, that is, COMP and MMP-3, and that plasma adiponectin levels, as well as adiponectin levels released by cultured cartilage, are associated with the radiographic severity of OA. Interestingly, the amount of adiponectin released by OA cartilage ex vivo also correlated positively with the production of inflammatory mediators NO and IL-6 and with the matrix-degrading enzyme MMP-3. Furthermore, adiponectin, when added at physiological concentrations to cultures of intact human OA cartilage or primary OA chondrocytes, enhanced the production of inflammatory and/or destructive factors NO, IL-6, MMP-1 and MMP-3. These findings suggest that adiponectin is associated with cartilage matrix degradation and has a role in the pathogenesis or as a biomarker in OA.
In the present study, we measured circulating levels of COMP and MMP-3 to evaluate the degree of ongoing cartilage destruction in OA . The level of serum COMP has been shown to correlate with the grade of OA assessed by the radiological score , which we also observed in this study. Also, the concentrations of MMP-3 have been reported to associate with joint space narrowing . The present results demonstrate for the first time that plasma adiponectin levels correlate with COMP and MMP-3, suggesting an association between adiponectin and the degree of ongoing cartilage matrix degradation.
We also found that plasma adiponectin levels and adiponectin amounts released by cultured OA cartilage ex vivo were higher in patients with radiographically advanced OA (grades 4 and 5 according to the Ahlbäck classification system) than in patients with less severe disease (Ahlbäck grades 1 to 3). This suggests that adiponectin is associated with cartilage degradation in patients with OA. Our results are supported by the recent studies by Ebina et al. , Giles et al.  and Klein-Wieringa et al. , who showed that circulating adiponectin correlates with joint erosions in RA patients. Additional support for our findings is provided by the study of Laurberg et al. , who reported elevated plasma adiponectin concentrations in OA patients as compared to healthy controls. In our study, adiponectin released by cultured cartilage also correlated positively with NO, IL-6 and MMP-3 production in the cartilage.
Two recent studies have reported somewhat different findings on the association between plasma adiponectin levels and radiographic findings. In the study by Honsawek et al. , adiponectin concentrations in plasma and synovial fluid were lower in patients with more severe knee OA measured according to the Kellgren-Lawrence Grading Scale. After they adjusted for gender, age and BMI, their plasma findings became nonsignificant, but the differences between adiponectin levels in synovial fluid within the radiographic groups remained significant. Most of their patients were female, which may at least partly explain the differences between their results and ours. Also, the two different radiographic scaling systems emphasize different findings. We chose to use Ahlbäck grading, since it tends to divide the end-stage OA patients less roughly than the Kellgren-Lawrence Grading Scale, as reported by, for example, Petersson et al. . Accordingly, most (80%) of our patients were scaled into the most severe Kellgren-Lawrence grade (grade 4). We included only male patients in the present study because gender is likely to be a confounding factor.
A study by Yusuf et al.  revealed that higher levels of plasma adiponectin decreased the risk for hand OA progression during a 6-year follow-up period as measured by radiographic changes. The findings of that study appear to be somewhat contradictory to our results and to those reported by the other research groups mentioned above. The differences may be explained by many factors, including different methodologies used to measure adiponectin, differences in patient characteristics and study protocols, gender differences (most of the patients in the study by Yusuf et al. were women) and possibly even by differences in the pathophysiologies of hand and knee OA. It is also possible that the significance of adiponectin varies according to the phase and severity of the OA process. It is noteworthy that all our patients had advanced OA and were undergoing joint replacement surgery. This made it possible to obtain simultaneous cartilage and blood samples. Lack of patients with less severe OA, however, limits our ability to generalize the results to milder cases.
An inverse relationship between adiponectin levels and BMI, especially visceral fat, has been reported in studies in which an endocrinological approach was used . However, no correlation between adiponectin and BMI was found in several recent clinical studies in which patients with OA or RA were investigated [35, 39, 42]. This was also the case within our group of OA patients. This may be explained by the fact that circulating concentrations of adiponectin can be regulated by various hormonal, nutritional or pharmacological factors and that adiponectin is produced not only by white adipose tissue but by other tissues as well . The question remains open whether there is such a systemic factor that affects the adiponectin levels in patients with arthritis or whether the joint disease itself rather than BMI might be a greater explanatory factor in defining the adiponectin levels in these patients.
As the clinical data suggest that the amount of adiponectin released by cartilage is related to the severity of cartilage degradation, we decided to study its possible mechanisms in OA cartilage. In agreement with recent findings [11, 14–16, 18], we found that adiponectin stimulated human OA cartilage and primary OA chondrocytes to produce NO, IL-6, MMP-1 and MMP-3, which are proinflammatory and catabolic mediators in OA [43–50]. In agreement with these findings, adiponectin was very recently reported to increase the production of chemokine IL-8 in human chondrocytes . MAPK inhibitors are under development for treatment of OA [26, 27], and MAPK pathways have been reported to be activated by adiponectin [51, 52]. Therefore, we studied whether MAPK signaling pathways are also activated by adiponectin in articular chondrocytes and whether they might mediate adiponectin's effects on NO, IL-6, MMP-1 and MMP-3 production. Adiponectin was found to activate the kinases p38, JNK and Erk1/2 at physiologically relevant concentrations. The p38 inhibitor decreased the production of all factors studied in a statistically significant manner, whereas Erk1/2 was involved in adiponectin-induced iNOS expression and NO production and JNK was involved in NO, iNOS and IL-6 production. These results, together with recently published findings [14, 18], show that MAPKs, especially p38, are significant pathways in adiponectin signaling in chondrocytes. Also, MAPK inhibitors are likely to attenuate adiponectin-induced gene expression in OA cartilage.
Adipokines, that is, hormones secreted by adipose tissue, have emerged as important modulating agents, not only in energy metabolism and appetite but also in the immune system and inflammation , and they are likely to have a role in mediating the connection between obesity and chronic inflammatory diseases. The actions of adiponectin, leptin, resistin and other, less studied adipokines in OA and other rheumatic diseases have recently been reviewed by Gómez et al.  and by Neumann et al. . The most studied adipokine in the pathophysiology of arthritis is leptin, which has been proven to have proinflammatory and catabolic roles in OA [8, 19, 54–58]. Knowledge about adiponectin in joint diseases has accumulated only lately. The present results, together with those described in the other recent reports, strongly suggest a proinflammatory and catabolic role for adiponectin in OA and RA cartilage.
We found that adiponectin was associated with markers and signs of cartilage degradation, that is, with circulating concentrations of COMP and MMP-3 and with radiographic severity of OA. Adiponectin was released by OA cartilage ex vivo, and it correlated with production of NO, IL-6 and MMP-3, which are important mediators in the pathogenesis of OA. Subsequent in vitro studies demonstrated that adiponectin, when added to the culture media, enhanced the production of NO, IL-6, MMP-1 and MMP-3 in OA cartilage and primary OA chondrocytes. Adiponectin also activated p38, Erk1/2 and JNK in chondrocytes, and the adiponectin-induced production of NO, IL-6, MMP-1 and MMP-3 were mediated by MAPKs, especially by p38. These findings strongly suggest that adiponectin is involved in the pathogenesis of joint inflammation and cartilage destruction in OA and may be a target for disease-modifying drug development.
body mass index
cartilage oligomeric matrix protein
Dulbecco's modified Eagle's medium
enzyme-linked immunosorbent assay
extracellular signal-regulated kinase 1/2
- HEK cells:
human embryonic kidney cells
inducible nitric oxide synthase
c-Jun N-terminal kinase
mitogen-activated protein kinase
tumor necrosis factor.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995, 270: 26746-26749. 10.1074/jbc.270.45.26746.
Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA. 2001, 98: 2005-2010. 10.1073/pnas.041591798.
Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002, 440: 213-221. 10.1016/S0014-2999(02)01430-9.
Sun Y, Xun K, Wang C, Zhao H, Bi H, Chen X, Wang Y: Adiponectin, an unlocking adipocytokine. Cardiovasc Ther. 2009, 27: 59-75. 10.1111/j.1755-5922.2008.00069.x.
Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006, 6: 772-783. 10.1038/nri1937.
Lago F, Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Gualillo O: Cardiometabolic comorbidities and rheumatic diseases: focus on the role of fat mass and adipokines. Arthritis Care Res (Hoboken). 2011, 63: 1083-1090. 10.1002/acr.20488.
Neumann E, Frommer KW, Vasile M, Müller-Ladner U: Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?. Arthritis Rheum. 2011, 63: 1159-1169.
Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O: What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol. 2011, 7: 528-536. 10.1038/nrrheum.2011.107.
Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J, Müller-Ladner U, Gay S: Adipocytokines in synovial fluid. JAMA. 2003, 290: 1709-1710. 10.1001/jama.290.13.1709-c.
Presle N, Pottie P, Dumond H, Guillaume C, Lapicque F, Pallu S, Mainard D, Netter P, Terlain B: Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis: contribution of joint tissues to their articular production. Osteoarthritis Cartilage. 2006, 14: 690-695. 10.1016/j.joca.2006.01.009.
Ehling A, Schäffler A, Herfarth H, Tarner IH, Anders S, Distler O, Paul G, Distler J, Gay S, Schölmerich J, Neumann E, Müller-Ladner U: The potential of adiponectin in driving arthritis. J Immunol. 2006, 176: 4468-4478.
Tan W, Wang F, Zhang M, Guo D, Zhang Q, He S: High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis. Semin Arthritis Rheum. 2009, 38: 420-427. 10.1016/j.semarthrit.2008.01.017.
Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT, Tsai SH: Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta. 2006, 1762: 711-718.
Kang EH, Lee YJ, Kim TK, Chang CB, Chung JH, Shin K, Lee EY, Lee EB, Song YW: Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res Ther. 2010, 12: R231-10.1186/ar3218.
Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM: Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-κB pathway. J Immunol. 2007, 179: 5483-5492.
Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, Gomez-Reino JJ, Gualillo O: A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage. 2008, 16: 1101-1109. 10.1016/j.joca.2007.12.008.
Choi HM, Lee YA, Lee SH, Hong SJ, Hahm DH, Choi SY, Yang HI, Yoo MC, Kim KS: Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther. 2009, 11: R161-10.1186/ar2844.
Tong KM, Chen CP, Huang KC, Shieh DC, Cheng HC, Tzeng CY, Chen KH, Chiu YC, Tang CH: Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem. 2011, 112: 1431-1440. 10.1002/jcb.23059.
Gómez R, Scotece M, Conde J, Gómez-Reino JJ, Lago F, Gualillo O: Adiponectin and leptin increase IL-8 production in human chondrocytes. Ann Rheum Dis. 2011, 70: 2052-2054. 10.1136/ard.2010.145672.
Lee SW, Kim JH, Park MC, Park YB, Lee SK: Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis. Scand J Rheumatol. 2008, 37: 260-268. 10.1080/03009740801910346.
Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, Oshima K, Matsuda M, Maeda K, Nakamura T, Ochi T, Shimomura I, Yoshikawa H, Hashimoto J: Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol. 2009, 28: 445-451. 10.1007/s10067-008-1074-y.
Giles JT, Allison M, Bingham CO, Scott WM, Bathon JM: Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Care Res. 2009, 61: 1248-1256. 10.1002/art.24789.
Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC, van Beelen E, Huizinga TW, van der Helm-van Mil A, Kloppenburg M, Toes RE, Ioan-Facsinay A: Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum. 2011, 63: 2567-2574. 10.1002/art.30449.
Honsawek S, Chayanupatkul M: Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res. 2010, 41: 593-598. 10.1016/j.arcmed.2010.11.007.
Yusuf E, Ioan-Facsinay A, Bijsterbosch J, Klein-Wieringa I, Kwekkeboom J, Slagboom PE, Huizinga TW, Kloppenburg M: Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis. 2011, 70: 1282-1284. 10.1136/ard.2010.146282.
Saklatvala J: Inflammatory signaling in cartilage: MAPK and NF-κB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets. 2007, 8: 305-313. 10.2174/138945007779940115.
Loeser RF, Erickson EA, Long DL: Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol. 2008, 20: 581-586. 10.1097/BOR.0b013e3283090463.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M: Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986, 29: 1039-1049. 10.1002/art.1780290816.
Ahlbäck S: Osteoarthrosis of the knee: a radiographic investigation. Acta Radiol Diagn (Stockh). 1968, Suppl 277: 7-72.
Nieminen R, Leinonen S, Lahti A, Vuolteenaho K, Jalonen U, Kankaanranta H, Goldring MB, Moilanen E: Inhibitors of mitogen-activated protein kinases downregulate COX-2 expression in human chondrocytes. Mediators Inflamm. 2005, 2005: 249-255. 10.1155/MI.2005.249.
Lahti A, Sareila O, Kankaanranta H, Moilanen E: Inhibition of p38 mitogen-activated protein kinase enhances c-Jun N-terminal kinase activity: implication in inducible nitric oxide synthase expression. BMC Pharmacol. 2006, 6: 5-
Korhonen R, Linker K, Pautz A, Förstermann U, Moilanen E, Kleinert H: Post-transcriptional regulation of human inducible nitric-oxide synthase expression by the Jun N-terminal kinase. Mol Pharmacol. 2007, 71: 1427-1434. 10.1124/mol.106.033449.
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982, 126: 131-138. 10.1016/0003-2697(82)90118-X.
Vuolteenaho K, Moilanen T, Jalonen U, Lahti A, Nieminen R, van Beuningen HM, van der Kraan PM, Moilanen E: TGFβ inhibits IL-1-induced iNOS expression and NO production in immortalized chondrocytes. Inflamm Res. 2005, 54: 420-427. 10.1007/s00011-005-1373-6.
Hao D, Li M, Wu Z, Duan Y, Li D, Qiu G: Synovial fluid level of adiponectin correlated with levels of aggrecan degradation markers in osteoarthritis. Rheumatol Int. 2011, 31: 1433-1437. 10.1007/s00296-010-1516-0.
Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegård D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M, for the OARSI FDA Osteoarthritis Biomarkers Working Group: Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011, 19: 515-542. 10.1016/j.joca.2010.08.019.
Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, Kraus VB: Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum. 1999, 42: 2356-2364. 10.1002/1529-0131(199911)42:11<2356::AID-ANR14>3.0.CO;2-R.
Lohmander LS, Brandt KD, Mazzuca SA, Katz BP, Larsson S, Struglics A, Lane KA: Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum. 2005, 52: 3160-3167. 10.1002/art.21345.
Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, Hetland ML, Hørslev-Petersen K, Hornung N, Poulsen JH, Flyvbjerg A, Stengaard-Pedersen K: Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol. 2009, 36: 1885-1891. 10.3899/jrheum.080907.
Petersson IF, Sandqvist L, Svensson B, Saxne T: Cartilage markers in synovial fluid in symptomatic knee osteoarthritis. Ann Rheum Dis. 1997, 56: 64-67. 10.1136/ard.56.1.64.
Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF: Adiponectin action from head to toe. Endocrine. 2010, 37: 11-32. 10.1007/s12020-009-9278-8.
Senolt L, Pavelka K, Housa D, Haluzík M: Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine. 2006, 35: 247-252. 10.1016/j.cyto.2006.09.002.
Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N: Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest. 1995, 96: 2357-2363. 10.1172/JCI118292.
Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, Di Battista JA, Martel-Pelletier J: Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum. 1998, 41: 1275-1286. 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T.
Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J: Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther. 2000, 6: 71-79. 10.1080/13684730050515796.
Attur MG, Dave M, Akamatsu M, Katoh M, Amin AR: Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine. Osteoarthritis Cartilage. 2002, 10: 1-4. 10.1053/joca.2001.0488. A published erratum appears in Osteoarthritis Cartilage 2003, 11:706
Mix KS, Sporn MB, Brinckerhoff CE, Eyre D, Schurman DJ: Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. Clin Orthop. 2004, 427 Suppl: S129-S137.
Järvinen K, Vuolteenaho K, Nieminen R, Moilanen T, Knowles RG, Moilanen E: Selective iNOS inhibitor 1400 W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA cartilage: survey of the effects of 1400 W on inflammatory mediators produced by OA cartilage as detected by protein antibody array. Clin Exp Rheumatol. 2008, 26: 275-282.
Cawston TE, Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 2006, 20: 983-1002. 10.1016/j.berh.2006.06.007.
Vuolteenaho K, Moilanen T, Knowles RG, Moilanen E: The role of nitric oxide in osteoarthritis. Scand J Rheumatol. 2007, 36: 247-258. 10.1080/03009740701483014.
Miyazaki T, Bub JD, Uzuki M, Iwamoto Y: Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun. 2005, 333: 79-87. 10.1016/j.bbrc.2005.05.076.
Wanninger J, Neumeier M, Weigert J, Bauer S, Weiss TS, Schäffler A, Krempl C, Bleyl C, Aslanidis C, Schölmerich J, Buechler C: Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-κB, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol. 2009, 297: G611-G618. 10.1152/ajpgi.90644.2008.
Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011, 11: 85-97. 10.1038/nri2921.
Otero M, Gomez Reino JJ, Gualillo O: Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-γ in human chondrocytes and ATDC5 chondrogenic cells. Arthritis Rheum. 2003, 48: 404-409. 10.1002/art.10811.
Otero M, Lago R, Lago F, Gomez Reino JJ, Gualillo O: Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Res Ther. 2005, 7: R581-R591. 10.1186/ar1708.
Otero M, Lago R, Gómez R, Lago F, Gomez-Reino JJ, Gualillo O: Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-γ synergistic NOS type II induction in chondrocytes. Life Sci. 2007, 81: 1452-1460. 10.1016/j.lfs.2007.09.007.
Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Päivärinta U, Moilanen T, Moilanen E: Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage: mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediators Inflamm. 2009, 2009: 345838-
Koskinen A, Vuolteenaho K, Nieminen R, Moilanen T, Moilanen E: Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol. 2011, 29: 57-64.
The excellent technical assistance of Meiju Kukkonen, Marja-Leena Lampén, Marja Jousimies, Elina Jaakkola, Petra Miikkulainen and Ella Lehto, and the skillful secretarial help of Heli Määttä are greatly acknowledged. Statistician Heini Huhtala is warmly thanked for her advice on the statistical analysis. This study was financially supported by The Academy of Finland, the Competitive Research Funding of the Pirkanmaa Hospital District, Päivikki ja Sakari Sohlberg Foundation, the Orion-Farmos Research Foundation and the Tampere Graduate Program in Biomedicine and Biotechnology.
The authors declare that they have no competing interests.
AK, SJ and KV were involved in the conception and design of the study, the laboratory analyses, calculation of the results and interpretation of the data, and they drafted the manuscript. RN was involved in the conception and design of the study, the laboratory analyses, the interpretation of the data and revising the manuscript. TM was involved in the conception and design of the study, selecting the patients, acquiring the patient samples, the interpretation of the data and revising the manuscript. EM was involved in the conception and design of the study, the interpretation of the data and writing the manuscript. All authors approved the final version of the manuscript.
Authors’ original submitted files for images
About this article
Cite this article
Koskinen, A., Juslin, S., Nieminen, R. et al. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways . Arthritis Res Ther 13, R184 (2011) doi:10.1186/ar3512
- Nitric Oxide
- Adiponectin Level
- Cartilage Oligomeric Matrix Protein
- Cartilage Degradation
- Plasma Adiponectin